Holen Sie sich die Stockscreener-App
150.73
0.80%
-1.28
Schlusskurs vom Vortag:
$152.01
Offen:
$152.3
24-Stunden-Volumen:
789.79K
Relative Volume:
0.42
Marktkapitalisierung:
$287.59B
Einnahmen:
$54.66B
Nettoeinkommen (Verlust:
$13.58B
KGV:
21.48
EPS:
7.0171
Netto-Cashflow:
$16.05B
1W Leistung:
+0.23%
1M Leistung:
+3.66%
6M Leistung:
+15.60%
1J Leistung:
+33.74%
1-Tages-Spanne:
$150.31
$152.49
1-Wochen-Bereich:
$149.54
$152.54
52-Wochen-Spanne:
$111.06
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
150.72 | 290.05B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,072.71 | 949.70B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.69 | 564.11B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
212.61 | 381.10B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.28 | 302.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.28 | 290.06B | 60.48B | 10.40B | 8.05B | 3.3297 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Argus | Hold → Buy |
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2026-01-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-12-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-09-12 | Herabstufung | Goldman | Neutral → Sell |
| 2025-08-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Herabstufung | UBS | Buy → Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2025-02-04 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-05 | Hochstufung | Stifel | Hold → Buy |
| 2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Fortgesetzt | Citigroup | Buy |
| 2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
| 2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
| 2021-03-10 | Herabstufung | Argus | Buy → Hold |
| 2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-04-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Bestätigt | Leerink Partners | Outperform |
| 2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Worried About Inflation? This International ETF Could Help Protect Your Portfolio - The Motley Fool
Novartis AG stock (CH0012005267): Q1 update, Sandoz deconsolidation and pharma focus draw investor a - AD HOC NEWS
Novartis AG stock (CH0012005267): oncology focus, new drug readout and solid 2025 guidance in view - AD HOC NEWS
NVS Stock Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis stock (CH0012005267): FDA progress and market focus - AD HOC NEWS
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock (CH0012005267): dividend profile and pipeline focus move into the spotlight - AD HOC NEWS
Novartis AG stock (CH0012005267): US expansion push with new Texas radioligand site - AD HOC NEWS
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis AG stock (CH0012005267): Recent 1.93% gain on SIX Swiss Exchange - AD HOC NEWS
Novartis AG stock (CH0012005267): NewEdge Wealth boosts stake amid mixed analyst views - AD HOC NEWS
NVSNovartis AG ADR Stock Price and Quote - Finviz
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities - ChartMill
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report - Sahm
Which Is a Better Investment, Novartis AG (ADR) or Pfizer Inc. Stock? - AAII.com
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers - Sahm
Novartis AG Stock (CH0012005267): Q1 Revenue Miss Triggers Decline - AD HOC NEWS
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility - ChartMill
Novartis CEO Flags Risks From Trump's MFN Drug Policy As Q1 Earnings Miss Estimates - Sahm
Earnings call transcript: Novartis Q1 2026 earnings miss forecasts, stock dips - Investing.com
Earnings call transcript: Novartis Q1 2026 earnings miss forecasts, stock dips By Investing.com - Investing.com Canada
Novartis (NYSE: NVS) Q1 2026 earnings dip as key drugs surge, Avidity deal closes - Stock Titan
Novartis slips after Q1 profit miss as sales fall on generic headwinds - Investing.com India
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed - ChartMill
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria - ChartMill
Novartis AG (NVS) Stock Price, Trades & News - GuruFocus
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA) - ChartMill
Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - GlobeNewswire Inc.
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
NVS Technical Analysis | Trend, Signals & Chart Patterns | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock (CH0012005267): Is its innovative drug pipeline strong enough to unlock new upside - AD HOC NEWS
Novartis AG (MEX:NVSN) Bonds - GuruFocus
Novartis AG (MEX:NVSN) Dividend - GuruFocus
Novartis AG stock (CH0012005267): Is its focused pharma strategy strong enough to unlock new upside? - AD HOC NEWS
Novartis AG (ADR) stock (CH0012005267): Why Google Discover changes matter more now - AD HOC NEWS
Novartis AG Stock Baskets | MEX:NVSN - GuruFocus
Novartis AG Stock Operating Data - GuruFocus
Novartis AG (ADR) stock (CH0012005267): Why its innovative drug pipeline matters more now for invest - AD HOC NEWS
Novartis AG (ADR) stock (CH0012005267): Why does its innovative drug pipeline matter more now for in - AD HOC NEWS
NVS Stock Quote Price and Forecast - CNN
Book value per share of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView — Track All Markets
Novartis AG stock (CH0012005267): Is its Innovative Medicines focus strong enough to unlock new upsi - AD HOC NEWS
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
6.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):